Elanco Animal Health (NYSE:ELAN) Price Target Raised to $27.00 at UBS Group

Elanco Animal Health (NYSE:ELAN) had its price target increased by UBS Group from $25.00 to $27.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

ELAN has been the subject of several other reports. Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a report on Thursday, July 17th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Finally, Stifel Nicolaus upped their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average price target of $20.29.

Elanco Animal Health Trading Down 0.1%

NYSE ELAN traded down $0.03 on Thursday, hitting $21.50. The company’s stock had a trading volume of 7,196,389 shares, compared to its average volume of 5,550,582. The company has a current ratio of 2.40, a quick ratio of 1.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $22.98. The firm has a market cap of $10.68 billion, a P/E ratio of 22.42, a PEG ratio of 3.24 and a beta of 1.71. The company’s 50-day simple moving average is $20.11 and its 200 day simple moving average is $16.07.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm earned $0.13 earnings per share. Elanco Animal Health’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Research analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ELAN. Syon Capital LLC purchased a new stake in shares of Elanco Animal Health in the third quarter worth approximately $214,000. Vanguard Group Inc. increased its stake in Elanco Animal Health by 1.6% in the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock worth $978,536,000 after purchasing an additional 759,623 shares during the period. Northwestern Mutual Investment Management Company LLC bought a new stake in shares of Elanco Animal Health during the third quarter worth $2,230,000. Fifth Third Bancorp boosted its stake in shares of Elanco Animal Health by 3,018.3% during the third quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after purchasing an additional 2,807 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Elanco Animal Health by 266.4% in the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock worth $38,635,000 after purchasing an additional 1,394,839 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.